TOP TEN perturbations for 1552940_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552940_at
Selected probe(set): 1552940_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552940_at (1552940_at) across 6673 perturbations tested by GENEVESTIGATOR:

cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):-1.4796686
Number of Samples:7 / 8
Experimental cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)

Relative Expression (log2-ratio):-1.3331656
Number of Samples:6 / 11
Experimental psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis twelve weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:
Control psoriasis study 5 (Zaba; lesional; etanercept; 1wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis one week after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-1.2331018
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

psoriasis study 5 (Zaba; lesional; baseline; resp.) / psoriasis study 5 (Zaba; non-lesional; baseline; resp.)

Relative Expression (log2-ratio):1.1687875
Number of Samples:11 / 11
Experimental psoriasis study 5 (Zaba; lesional; baseline; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis (Zaba (Amgen) data set), classified as responders to etanercept treatment.
Control psoriasis study 5 (Zaba; non-lesional; baseline; resp.)
Non-lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis (Zaba (Amgen) data set), classified as responders to etanercept treatment.

psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 2wk; resp.)

Relative Expression (log2-ratio):-1.145515
Number of Samples:6 / 11
Experimental psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis twelve weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:
Control psoriasis study 5 (Zaba; lesional; etanercept; 2wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis two weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.94720507
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.9349065
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 4wk; resp.)

Relative Expression (log2-ratio):-0.89952993
Number of Samples:6 / 9
Experimental psoriasis study 5 (Zaba; lesional; etanercept; 12wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis twelve weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:
Control psoriasis study 5 (Zaba; lesional; etanercept; 4wk; resp.)
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis four weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code:

psoriasis study 24 (lesional; baseline; etarnecept; non-responder) / psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):0.89015484
Number of Samples:13 / 13
Experimental psoriasis study 24 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder) / psoriasis study 24 (lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):-0.8607645
Number of Samples:10 / 13
Experimental psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 50 mg etanercept and assigned as non-responders. Etanercept was administered subcutaneously in dose of 50 mg twice weekly. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.